HeXun Biosciences and JY BioMed have signed an exclusive licensing agreement for “Human-Derived Umbilical Cord Mesenchymal Stem Cell Drug Production Technology.” Following the licensing of related production technology for human umbilical cord mesenchymal stem cells (UC-MSCs) to JY BioMedical, both parties will collaborate to develop specific MSC-derived exosomes using specialized techniques and data.

Dendritic cells (DCs) are powerful antigen-presenting cells crucial for initiating immune responses. DC-based tumor vaccines have been shown to safely stimulate anti-tumor-associated antigen (TAA) responses, as exemplified by Sipuleucel-T (Provenge), an FDA-approved autologous DC vaccine for castration-resistant prostate cancer. However, such vaccines have generally shown limited clinical efficacy, necessitating strategies to improve their effectiveness.